Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study.

< BACK TO ARCHIVE


Papers: 16 Apr 2022 - 22 Apr 2022


Human Studies, Pharmacology/Drug Development


2022


Front Neurol


http://www.ncbi.nlm.nih.gov/pubmed/35432170?dopt=Abstract


13

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study.

Authors

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study.
Pellesi L, Al-Karagholi M A-M, De Icco R, Chaudhry B A, Lopez C L, Snellman J, Hannibal J, Amin F M, Ashina M
Front Neurol. 2022; 13:871176.
PMID: 35432170.

Abstract

The activation of perivascular fibers and the consequent release of vasoactive peptides, including the vasoactive intestinal polypeptide (VIP), play a role in migraine pathogenesis. A 2-h infusion of VIP provoked migraine, but the mechanisms remain unknown. We investigated whether 2-h infusion of VIP caused alterations in plasma levels of the calcitonin gene-related peptide (CGRP) and whether any changes might be related to the induced migraine attacks.
Read This Paper